| ²é¿´: 1746 | »Ø¸´: 9 | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
Ãγ¾ÒÝгæ (³õÈëÎÄ̳)
|
[ÇóÖú]
ÇóÖú£¬ÕâÑù˵ÎÄÕÂÄܲ»Äܱ»½ÓÊÜ£¿
|
||
|
±¾ÈËǰһ¶Îʱ¼äÔÚinternational immunopharmacologyÉÏÍ·ÁËһƪÎÄÕ£¬Ó°ÏìÒò×Ó²»¸ß2.3°É£¬Éó¸åÒâ¼û»ØÀ´ÁË£¬ÓÐÒ»¸öÉó¸åÈ˾ÍÌáÁË3¸öÎÊÌ⣬»¹¶¼ÊÇСÎÊÌ⣬»ù±¾Ã»Ê²Ã´Ê£¬²»¹ýÁíÒ»¸öÉó¸åÈËÈ´ÊÇÕâô˵µÄ Reviewer #2: The authors of this study claimed that synergistic effects of blocking IL-1beta and IL-17A could suppress the rheumatoid development in CIA mouse model. Blocking of IL-1 and IL-17signaling pathway have been shown playing function in delaying or preventing the development of rheumatoid arthritis. In this study, the authors did not point out any new information in addition to well-documented. Detailed mechanism on how those two molecules play a synergistic effect is more favored. And there are also several other questions. 1. The whole experiment was done in DBA mice, why humanized antibodies were used? Please justify the structural similarity of both human and murine IL-1 beta and IL-17A as well as the crossreactivities of those blocking antibody. 2. In 3.4 and 3.5, as author stated, it should be ex vivo experiment but not in vitro. ÇóÖú´óÉñÃÇÕâÖÖÒâ¼ûÓ¦¸ÃÔõô°ìÄØ£¬ÎÊÌâÑϲ»ÑÏÖØ°¡£¿ÎÒ×îºÃÔõô»Ø´ðËû£¬ÒѾÀ§ÈźþÃÁË |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
decision in progress |
» ²ÂÄãϲ»¶
Ò»Ö¾Ô¸985£¬±¾¿Æ211£¬0817»¯Ñ§¹¤³ÌÓë¼¼Êõ319Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
Ò»Ö¾Ô¸¼ªÁÖ´óѧ²ÄÁÏѧ˶321Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
Ò»Ö¾Ô¸Öк£Ñó²ÄÁϹ¤³Ìר˶330·ÖÇóµ÷¼Á
ÒѾÓÐ6È˻ظ´
Ò»Ö¾Ô¸Î÷°²½»Í¨´óѧ²ÄÁϹ¤³Ìרҵ 282·ÖÇóµ÷¼Á
ÒѾÓÐ3È˻ظ´
332Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
294Çóµ÷¼Á²ÄÁÏÓ뻯¹¤×¨Ë¶
ÒѾÓÐ7È˻ظ´
281Çóµ÷¼Á£¨0805£©
ÒѾÓÐ17È˻ظ´
267Ò»Ö¾Ô¸ÄϾ©¹¤Òµ´óѧ0817»¯¹¤Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
0817µ÷¼Á
ÒѾÓÐ3È˻ظ´
½¹ÂÇ
ÒѾÓÐ13È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ÇóÖú£º²»ÖªµÀÎÄÕÂÓÐûÓÐËÍÉó£¿AMIS
ÒѾÓÐ4È˻ظ´
½ô¼±ÇóÖú£¬Ä³ÔÓÖ¾2012ÄêSCI²»ÊÕ¼ÁË£¬µ«2011Ä껹ÓÐһƪÎÄÕ´ýÊÕ¼£¬³·¸å²»³·¸å£¿
ÒѾÓÐ20È˻ظ´
ÇóÖú£ºÎÄÕ±»¾ÜºóÄÜ·ñÐ޸ĺóÔÙÖØÍ¶¸ÃÔÓÖ¾
ÒѾÓÐ15È˻ظ´
ÇóÖú£¬ÎÒÄܲ»ÄÜÓÃÕâÆªÎÄÕ±ÏÒµ£¿
ÒѾÓÐ23È˻ظ´
¡¾ÇóÖú¡¿ÎÞÓ¢Óï³É¼¨£¬ÓÐÎÄÕ£¬ÄܳöÈ¥²»£¿£¿
ÒѾÓÐ17È˻ظ´
¡¾ÇóÖú¡¿ÔõÑùÄ£·ÂǰÈ˵ÄÎÄÕ²Ų»Ëã³Ï®£¿
ÒѾÓÐ8È˻ظ´
¡¾ÇóÖú¡¿¿´²»¶®ÎÄÕ¼«Í¼·ÖÎö£¬Çë°ïæ½âÊÍһϣ¡(ͼƬÒÑÄÜÏÔʾ)
ÒѾÓÐ12È˻ظ´
visitor958
ÖÁ×ðľ³æ (ÎÄ̳¾«Ó¢)
IEEEÔÓÖ¾Óë»áÒéר¼Ò
- Ó¦Öú: 2283 (½²Ê¦)
- ¹ó±ö: 0.05
- ½ð±Ò: 17310
- É¢½ð: 2544
- ºì»¨: 76
- Ìû×Ó: 15735
- ÔÚÏß: 2926.6Сʱ
- ³æºÅ: 489254
- ×¢²á: 2008-01-01
- רҵ: IEEE
5Â¥2012-11-19 20:43:28
Ãγ¾ÒÝ
гæ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 8.8
- Ìû×Ó: 12
- ÔÚÏß: 14Сʱ
- ³æºÅ: 1466114
- ×¢²á: 2011-10-29
- רҵ: ¿¹Ì幤³Ìѧ
2Â¥2012-11-19 16:29:25
nono2009
³¬¼¶°æÖ÷ (ÎÄѧ̩¶·)
No gains, no pains.
-

ר¼Ò¾Ñé: +21105 - SEPI: 10
- Ó¦Öú: 28684 (Ժʿ)
- ¹ó±ö: 513.911
- ½ð±Ò: 2555230
- É¢½ð: 27828
- ºì»¨: 2148
- ɳ·¢: 66666
- Ìû×Ó: 1602255
- ÔÚÏß: 65200.9Сʱ
- ³æºÅ: 827383
- ×¢²á: 2009-08-13
- ÐÔ±ð: GG
- רҵ: ¹¤³ÌÈÈÎïÀíÓëÄÜÔ´ÀûÓÃ
- ¹ÜϽ: ¿ÆÑмҳﱸίԱ»á
3Â¥2012-11-19 19:42:59
xianjin1985
Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 9 (Ó×¶ùÔ°)
- ½ð±Ò: 7176.5
- É¢½ð: 3036
- ºì»¨: 1
- ɳ·¢: 1
- Ìû×Ó: 1907
- ÔÚÏß: 391.7Сʱ
- ³æºÅ: 551105
- ×¢²á: 2008-04-25
- ÐÔ±ð: GG
- רҵ: È«Çò±ä»¯Éú̬ѧ
4Â¥2012-11-19 20:15:38













»Ø¸´´ËÂ¥